Liver disease with extrahepatic peritoneal disease

Recent oncologic guidelines for metastatic colorectal cancer have incorporated peritoneal disease into treatment frameworks, emphasizing patient selection and multidisciplinary decision-making. The coexistence of liver and peritoneal metastases (PM) is a marker of biologically aggressive disease with a dismal prognosis. As a rule, simultaneous PM had excluded patients from hepatic resection, leading to reliance on systemic therapy alone. However, recent advances in systemic treatment, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have challenged this paradigm. Contemporary systematic reviews have shown that combined CRS/HIPEC and liver-directed therapy can provide significant survival benefits in selected patients. The selection of patients for surgery with concurrent liver and peritoneal metastases should be done with even greater caution. This article synthesizes the available evidence and highlights evolving strategies for patients with liver disease and extrahepatic peritoneal involvement.